* Pyxis Oncology Inc reported a quarterly adjusted loss of 6 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -55 cents. The mean expectation of six analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -34 cents to -12 cents per share.
* Revenue was $16.15 million; analysts expected $4.13 million.
* Pyxis Oncology Inc's reported EPS for the quarter was a loss of 6 cents.
* The company reported a quarterly loss of $3.26 million.
* Pyxis Oncology Inc shares had risen by 0.7% this quarter and gained 138.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 25.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Pyxis Oncology Inc is $8.50 This summary was machine generated from LSEG data May 14 at 02:28 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.25 -0.06 Beat
Dec. 31 2023 -0.47 -0.33 Beat
Sep. 30 2023 -0.51 -0.56 Missed
Jun. 30 2023 -0.65 -0.41 Beat
Comments